PT  - JOURNAL ARTICLE
AU  - Alizon, Samuel
AU  - Haim-Boukobza, Stéphanie
AU  - Foulongne, Vincent
AU  - Verdurme, Laura
AU  - Trombert-Paolantoni, Sabine
AU  - Lecorche, Emmanuel
AU  - Roquebert, Bénédicte
AU  - Sofonea, Mircea T.
TI  - Rapid spread of the SARS-CoV-2 <em>δ</em> variant in the area of Paris (France) in June 2021
AID  - 10.1101/2021.06.16.21259052
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.16.21259052
4099  - http://medrxiv.org/content/early/2021/06/20/2021.06.16.21259052.1.short
4100  - http://medrxiv.org/content/early/2021/06/20/2021.06.16.21259052.1.full
AB  - Analysing 5,061 variant-specific tests performed on SARS-CoV-2 positive samples collected in France between 31 May and 8 June 2021 reveals a rapid growth of the δ variant in the Île-de-France region. The next weeks will prove decisive but the magnitude of the estimated transmission advantage (with a 95% confidence interval between 67 and 120%) could represent a major challenge for public health authorities.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04738331Funding StatementThis study did not receive any specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the IRB of the University Hospital of Montpellier (France).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for the analyses will be published along with the scripts upon acceptance.